Key result
A sensitized mutagenesis screen in Factor V Leiden mice identified two genomic regions, including the Factor 3 and Actr2 genes, that reduce venous thromboembolism susceptibility.
A sensitized mutagenesis screen in Factor V Leiden mice identified Factor 3 and Actr2 as critical genes for regulating blood-clotting risk and VTE susceptibility.
Significance Venous thromboembolism (VTE) is a common disease characterized by the formation of inappropriate blood clots. Inheritance of specific genetic variants, such as the Factor V Leiden polymorphism, increases VTE susceptibility. However, only ∼10% of people inheriting Factor V Leiden develop VTE, suggesting the involvement of other genes that are currently unknown. By inducing random genetic mutations into mice with a genetic predisposition to VTE, we identified two genomic regions that reduce VTE susceptibility. The first includes the gene for blood coagulation, Factor 3, and its role was confirmed by analyzing mice with an independent mutation in this gene. The second contains a mutation in the Actr2 gene. These findings identify critical genes for the regulation of blood-clotting risk.
No takes yet. Share an insight, caveat, or question.
Westrick et al. (2017) studied Venous thromboembolism (VTE). Random genetic mutations was evaluated on VTE susceptibility. A sensitized mutagenesis screen in Factor V Leiden mice identified two genomic regions, including the Factor 3 and Actr2 genes, that reduce venous thromboembolism susceptibility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: